ERYTECH provides an update on its activities and publishes its results for the fourth quarter and the full year 2022 – 03/23/2023 at 22:05
Announcement of the combination with Pherecydes with the aim of creating a world leader in extended phage therapy targeting antibiotic-resistant pathogenic bacteria
Implementation of a deep restructuring that led to the reduction of the size of the team by around 75% since the beginning of 2022
Cash and cash equivalents of €38.8 million ($41.5 million) as of December 31, 2022
Cambridge, MA (US) and Lyon (France), March 22, 2023 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provides an update on its activities and presents its financial results for the fourth quarter and the full year 2022.
If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]